CuringHeartDisease

Always searching for a cure
Peter Megdal, PhD
Join Our Cause

Revised: July 16, 2026

Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression

By: Peter Megdal PhD

How to Use This Article

Choose your format
Easy Read
Deep Dive
YouTube
SPOTIFY
SLIDE DECK
  • Based on peer-reviewed medical research
  • Same evidence cardiologists use
  • Written in clear language for the public
  • Look for underlined terms and related links

Medical disclaimer: This article is for education only and is not medical advice. Always consult your clinician for personal guidance.

Easy Read

1. The Mystery of the Healthy Lab Report

Imagine a man named Sam. Sam is the kind of person we all want to be. He runs five miles every morning, he eats plenty of colorful vegetables, and he avoids junk food. When Sam went to his yearly check-up, his doctor had great news. The doctor looked at Sam’s blood test and said, “Your numbers are perfect! Your total cholesterol is low, and your LDL looks great. Your heart is in tip-top shape.”

Sam felt safe and happy, but just two weeks later, he ended up in the hospital. He had suffered a major heart attack.

How could a “healthy” person with “perfect” numbers have a heart attack? The answer is that Sam’s lab report was like a blurry photo. It showed the big shapes, but it missed the dangerous details. For years, doctors only looked at “Total Cholesterol,” but science has moved forward. We now have a “New View” of heart risk. To see the full picture, we must look at a special trio of markers: ApoB, Lp(a), and hsCRP. This article will explain why these three are the real keys to your health.

2. Takeaway #1: It’s Not the Weight of the Butter, It’s the Number of Boats (The ApoB Story)

For a long time, doctors focused on “LDL-C.” This test measures the weight of the cholesterol in your blood. But cholesterol does not just float around by itself like oil in water. It travels inside little “boats” called particles.

Think about a busy highway. If you want to know how likely a car crash is, you do not want to know the total weight of all the people inside the cars. You want to know how many cars are on the road! More cars mean more chances for a collision. In your blood, Apolipoprotein B (ApoB) is the best way to count those cars.

The Particle Counter Every single “bad” particle that can cause heart disease has exactly one molecule of ApoB on it. This makes it a perfect biological counter. If the lab finds 100 ApoB molecules, you have exactly 100 dangerous particles. It is much more accurate than the old way.

Most doctors still use a math trick called the “Friedewald equation” to guess your LDL weight. This trick is not always right, especially if you have high blood fats or if you just ate. ApoB is a direct count, so it tells the truth even when the old tests are confused.

Why the “Weight” Can Lie Sometimes, your “LDL weight” is low, but your “ApoB count” is high. Doctors call this “discordance.” This often happens to people with diabetes or those who carry extra weight. Their “boats” are very small, so they don’t weigh much, but they have way too many of them on the road!

Why ApoB is the better way to check your heart:

  • It counts the cars, not the people: It measures the actual number of dangerous particles.
  • It is a direct measurement: It does not use the Friedewald equation to guess your risk.
  • It sees hidden danger: It finds risk in people who have “normal” LDL but too many particles.

3. Takeaway #2: The “Sticky Velcro” Effect (How Plaque Actually Starts)

Heart disease does not happen just because you have fat in your blood. It starts when those particles get trapped inside the walls of your arteries. This is a process called “Subendothelial Retention.”

Think of the inside of your artery like a very smooth plastic slide. Usually, things just slide right past and keep moving. But your artery walls have parts that are “negatively charged.” The ApoB particles have “positively charged” parts. Just like two magnets, they pull toward each other. When they touch, the particles get stuck like they are attached with Velcro.

Once they are stuck, they cannot get out. They stay in the wall and start to change.

“Atherosclerosis doesn’t start because the blood contains ‘too much cholesterol’ in the abstract. It starts because too many atherogenic particles are circulating, and a fraction of them get trapped in the artery wall.”

Once trapped, these particles become “oxidized,” which means they go sour or “rust.” This sends out a “danger signal” to your body. Your immune system sends in special cleanup cells to eat the rusted particles. These cells get so full of fat that they turn into “foam cells.” This is how the “gunk” or plaque in your heart starts to build up and block your blood flow.

4. Takeaway #3: The Genetic Lottery You Can’t Outrun (Understanding Lp(a))

There is a very special, very “sticky” particle called Lipoprotein(a), or Lp(a). This is the “genetic” part of your cholesterol. Most of your numbers change if you eat more salads or run more miles, but Lp(a) is different. It is “70% to 90% heritable.” This means you get your level from your parents, and it stays the same your whole life, no matter how much you exercise.

The Chain Analogy Scientists look at things called “Kringle IV” repeats to understand your Lp(a). Think of these like links on a chain. Some people are born with long chains, and some have short chains.

  • Short chains (Fewer repeats): Your body makes more Lp(a) particles.
  • Long chains (More repeats): Your body makes fewer Lp(a) particles.

The Double Threat Lp(a) is much more dangerous than regular LDL for two reasons. First, it carries “oxidized phospholipids.” These are like tiny firecrackers that cause extra inflammation and damage. Second, Lp(a) looks almost exactly like a molecule called “plasminogen” that helps your body break up blood clots. Because they look the same, Lp(a) gets in the way. It acts as a “clot starter.” It stops your body from clearing out clots, which can lead directly to a heart attack.

5. Takeaway #4: The Smoke Detector in Your Blood (The Role of hsCRP)

Heart disease is not just about particles; it is also about “inflammation.” Inflammation is what happens when your body is “on fire” or irritated. To measure this, doctors use a test called hsCRP.

Think of hsCRP as a “smoke detector.” It does not tell you exactly where the fire is. You could have a fire in your heart, or you could have one in your joints. But it warns you that the “building” (your body) is “hot.”

It might seem strange that a test for “hot” cells could predict a heart attack, but science shows us exactly why. There was a famous study called the JUPITER Trial. The scientists looked at people who had “normal” cholesterol levels but “high” hsCRP on their smoke detectors. Even though their cholesterol looked fine, these people were still having heart attacks because of the hidden inflammation! When they took medicine to lower both the inflammation and the cholesterol, their risk of heart problems dropped by 44%. This proved that “good” cholesterol is not enough if your smoke detector is going off.

6. Takeaway #5: The “Triple Threat” Power-Up (Synergistic Risk)

ApoB, Lp(a), and hsCRP are each dangerous on their own. But when you have all three, the danger does not just add up—it multiplies! This is called “Synergistic Risk.”

In the medical world, doctors use a term called MACE. This stands for Major Adverse Cardiovascular Events. This is just a short way of saying serious heart events, like a heart attack or a stroke. A study of over 320,000 people showed that having all three markers high creates a massive jump in MACE risk.

Marker Levels Heart Event (MACE) Risk Elevation
All Markers Low 0% (Baseline)
High LDL-C Only +13%
High Lp(a) Only +8%
High hsCRP Only +6%
All Three Markers High +77%

If you look at the table, 13 + 8 + 6 only equals 27. But in the human body, they work together to reach 77%. Having too many particles (ApoB) that are extra sticky (Lp(a)) in a body that is “on fire” (hsCRP) is the “Triple Threat” that causes the most damage.

7. Takeaway #6: Smoking vs. Lipids (The Surprising Comparison)

We all know that smoking is very bad for your heart. It creates stress and hurts the lining of your arteries. A huge study called INTERHEART looked at people in 52 countries to see what causes the most heart attacks worldwide.

Smoking is very dangerous. It has an “Odds Ratio” of 3.63, which means smokers are over three times more likely to have a heart attack. However, high lipid levels (the ratio of your ApoB particles) actually cause more heart attacks across the whole world. This is because high lipids are much more common than smoking. In science terms, lipids have a “Population Attributable Risk” of 54.1%. This means over half of all heart attacks are linked to bad lipid levels.

The Female Paradox The study also found something very important for women. Even though smoking is bad for everyone, it is about 50% more dangerous for a woman’s heart than for a man’s heart. This shows that we cannot use a “one-size-fits-all” map for heart health. Every person is different.

8. Takeaway #7: The Statin Surprise and the Future of Treatment

Many people take “statins” to lower their cholesterol. Statins are wonderful at lowering ApoB and LDL, which helps many people stay safe. But there is a surprise: statins can actually increase your Lp(a) levels by about 10% to 20%.

This is why some people still have heart attacks even when their LDL is very low. Doctors call this “residual risk.” It is the danger that is left over after the standard medicine does its job.

The good news is that new “targeted tools” are coming soon. Because statins don’t lower Lp(a), scientists are making new medicines called “ASOs” and “siRNA.” These are like “smart bombs” that go after the Lp(a) specifically. In early tests, these new tools have lowered Lp(a) by 80% to 90%! This will help doctors treat the genetic risk that diet, exercise, and statins cannot touch.

9. Conclusion: Your Integrated Map to a Longer Life

We are moving away from the 1970s view of heart health. Your heart is not just one number on a page. It is an “Integrated Risk Map.” To see your clear picture, you need to ask three big questions:

  1. ApoB: How many “cars” are on my highway?
  2. Lp(a): Did I lose the genetic lottery with sticky particles?
  3. hsCRP: Is my “smoke detector” telling me there is a fire?

Let’s go back to Sam. After his heart attack, Sam found a doctor who used the “New View.” They tested his ApoB and his Lp(a). It turned out that while Sam’s LDL weight was low, his Lp(a) was very high. He had “sticky” particles he was born with, and his old test never saw them. Now, Sam is on the right treatment and is back to running his morning miles—this time with a clear map for his future.

Do you know your particle count and your genetic risk? If you are still relying on old “total cholesterol” numbers, you are still looking at a blurry photo. It is time to see the truth and protect your heart.

Deep Dive

How we think about cardiovascular risk has changed a lot. We used to focus on total cholesterol and later LDL cholesterol (LDL-C) as the main villains. Now, the picture is more precise: risk is driven by how many atherogenic particles are circulating, which genetically “high-risk” particles are present, and how much inflammation is active in the vessel wall. At the heart of this newer view is a practical triad of biomarkers: apolipoprotein B-100 (ApoB), which counts the number of atherogenic lipoprotein particles;¹ lipoprotein(a) [Lp(a)], a mostly inherited LDL-like particle with added thrombotic risk;² and high-sensitivity C-reactive protein (hsCRP), a marker that tracks systemic and vascular inflammation.³

LDL-C still matters and remains the standard therapeutic target, but clinical experience (and growing evidence) shows that LDL-C can miss important risk—especially when ApoB is high, Lp(a) is elevated, or hsCRP suggests ongoing inflammation.⁴ In many patients, these three factors stack together and create risk that feels “out of proportion” to traditional lipid panels. When you compare this biochemical and genetic risk profile with behavioral insults like cigarette smoking, the hierarchy of risk becomes even more nuanced, reinforcing the need for personalized prevention strategies in both primary and secondary prevention.⁵

The Molecular Framework of Apolipoprotein B-100 and Particle Pathogenicity

Atherosclerosis doesn’t start because the blood contains “too much cholesterol” in the abstract. It starts because too many atherogenic particles are circulating, and a fraction of them get trapped in the artery wall.⁶ The single best way to understand this is to think in terms of particle number, not just cholesterol mass.⁶

Apolipoprotein B (ApoB) is the key structural protein on all potentially atherogenic lipoproteins: very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and also lipoprotein(a).⁸ Each of these particles carries exactly one ApoB-100 molecule, which makes ApoB a convenient biological “counter”: the ApoB concentration in plasma tells you how many atherogenic particles are present.⁷

This is why relying exclusively on LDL-C can be misleading in some common clinical settings—especially hypertriglyceridemia, metabolic syndrome, and type 2 diabetes.⁶ In these states, LDL particles often carry less cholesterol per particle, shifting toward small, dense LDL (sdLDL). That means a patient can show an “acceptable” LDL-C value while still having a high number of LDL particles—a pattern often described as LDL-C/ApoB discordance.⁹ ApoB measurement bypasses that limitation by directly reflecting particle burden, which better captures the likelihood of lipoprotein entry into the arterial intima.⁷

Mechanisms of Subendothelial Infiltration and Retention

Atherosclerosis begins when the endothelium—normally a smooth barrier—becomes more permeable or dysfunctional, often due to shear stress, oxidative injury, metabolic dysfunction, or chemical exposure (including tobacco smoke).¹¹ Once that barrier is compromised, ApoB-containing particles can move into the arterial intima.¹⁰

What matters next is not only entry, but retention. In the subendothelial space, ApoB particles interact with the extracellular matrix rather than simply drifting by concentration gradients.¹² ApoB-100 contains positively charged regions that bind to negatively charged sulfate groups on arterial proteoglycans. This electrostatic interaction is one of the reasons particles become “stuck” in the vessel wall—an essential early step in plaque formation.¹⁰ Once trapped, particles undergo oxidative and enzymatic modification, generating oxidized lipoproteins that are far more inflammatory and immunogenic than native particles.¹³

These modified particles act like danger signals. They recruit monocytes, promote macrophage uptake through scavenger receptors, and drive the formation of lipid-laden foam cells—one of the earliest histologic hallmarks of atherosclerotic lesions.¹³

Stoichiometry and Diagnostic Precision of ApoB

ApoB’s clinical advantage is not only conceptual—it’s practical. Much of routine LDL-C reporting still depends on calculated methods, most commonly the Friedewald equation:¹⁴

This approach becomes less accurate when triglycerides are elevated (typically when TG exceed ~3.5–4 mmol/L) or when blood is drawn in a non-fasting state.¹⁴ ApoB, in contrast, is measured directly through immunoassays (immunoturbidimetric or immunonephelometric methods) that have been internationally standardized.¹⁵ In practice, ApoB tends to show lower analytic bias and better reproducibility than calculated lipid measures, which is why it is increasingly favored for assessing particle-driven risk.⁷

Physiological Metric Diagnostic Method Sensitivity to Fasting
LDL-C Cholesterol mass Calculation (Friedewald)
ApoB-100 Particle count (1:1 ratio) Direct measurement
Non-HDL-C All atherogenic cholesterol Calculation (TC − HDL-C)
Lp(a) Genetic particle subtype Immunoturbidimetric

Lipoprotein(a): The Genetic Vanguard of Atherothrombosis

Lp(a) is one of the most clinically important (and frustrating) lipoproteins because it is largely genetically determined and minimally affected by lifestyle changes. Structurally, Lp(a) looks like an LDL particle with an attached additional protein—apolipoprotein(a) [apo(a)]—linked to ApoB-100 by a disulfide bond.² It’s this additional apo(a) component that makes Lp(a) biologically distinctive and often more dangerous than standard LDL. Some estimates suggest it may be several-fold more potent as a driver of cardiovascular disease than LDL alone.¹⁶

Genetic Regulation and Kringle IV Complexity

Lp(a) levels are mainly controlled by the LPA gene on chromosome 6q26–q27. Lp(a) concentration is typically 70% to 90% heritable and remains relatively stable over a lifetime, unlike LDL-C which can shift substantially with diet, weight loss, and medications.¹⁷ The striking variability in Lp(a) between individuals—sometimes over a 1000-fold range—comes largely from copy-number variation in the Kringle IV type 2 (KIV2) repeats within apo(a).¹⁸

Kringle domains are looped structures stabilized by disulfide bonds. Apo(a) contains multiple kringle subtypes (KIV1–KIV10), but KIV2 is the one that varies widely across people. Those with fewer KIV2 repeats generally make smaller apo(a) isoforms and tend to have higher plasma Lp(a) levels. This inverse relationship between apo(a) size and Lp(a) concentration explains much of the genetic contribution to cardiovascular risk from Lp(a).¹⁹

The Dual Mechanisms of Lp(a) Pathogenicity

Lp(a) increases risk through two main pathways that overlap in real-world disease: a pro-atherogenic/pro-inflammatory pathway and a pro-thrombotic/anti-fibrinolytic pathway.²²

Atherogenic and pro-inflammatory drive: Like other ApoB particles, Lp(a) can cross the endothelium and accumulate in the intima. But Lp(a) is also a major carrier of oxidized phospholipids (OxPL) in plasma.²⁰ OxPL behave like strong inflammatory ligands, promoting endothelial activation, smooth muscle proliferation, macrophage dysfunction, and sometimes apoptosis—features that contribute to plaque growth and instability.²⁰

Thrombotic and anti-fibrinolytic interference: Apo(a) shares significant structural homology with plasminogen.²¹ Because of this resemblance, Lp(a) can compete with plasminogen for binding sites on fibrin, interfering with plasmin generation and impairing fibrinolysis.²² In effect, Lp(a) encourages thrombus persistence, increasing the chance that plaque rupture leads to a clinically significant occlusive event such as myocardial infarction.²²

Systemic Inflammation and the Sentinel Role of hsCRP

Atherosclerosis is now widely understood as a chronic inflammatory condition affecting the arterial wall.²³ Among the inflammatory biomarkers available clinically, hsCRP remains the most commonly used and best standardized.³ hsCRP does not tell you where inflammation is coming from, but persistent low-grade elevation strongly correlates with vascular inflammatory risk.³

The NLRP3 Inflammasome and CRP Induction

When cholesterol crystals and oxidized ApoB particles build up in the intima, they activate immune pathways, including the NLRP3 inflammasome in macrophages.²⁴ This leads to processing of pro-interleukin-1β and pro-IL-18 into active cytokines.²⁴ These cytokines stimulate downstream IL-6 signaling, which triggers the liver to synthesize and release CRP.²⁵

CRP can spike dramatically during infection, but chronically elevated hsCRP (often defined as hsCRP ≥ 2 mg/L) behaves more like a “smoke detector” for ongoing vascular inflammation and future cardiovascular events.³

Lessons from the JUPITER Trial

The JUPITER trial was a turning point because it showed that inflammatory risk can identify high-risk patients even when LDL-C looks fine.²⁶ The study enrolled individuals with LDL-C below usual treatment thresholds (<130 mg/dL) but with hsCRP ≥2.0 mg/L. Participants receiving rosuvastatin 20 mg daily had a 44% reduction in major cardiovascular events.²⁶ Clinically, the takeaway was simple: some patients carry substantial risk through inflammation even when they do not appear “hyperlipidemic” by LDL-C alone.

Mapping the Interplay: Synergistic Risk and Pathogenic Cross-talk

ApoB, Lp(a), and hsCRP do not operate in isolation. Their relationship is better described as interactive, with overlapping mechanisms that can amplify each other’s harm.⁴

High ApoB means more particles enter the vessel wall and more substrate becomes available for oxidative modification. Those modified particles intensify inflammation, raising hsCRP. Inflammation then further disrupts endothelial function, making it easier for additional ApoB particles to enter—creating a self-reinforcing loop.²³

This synergy shows up clearly in large population studies. In a study of over 320,000 UK Biobank participants, LDL-C, Lp(a), and hsCRP were each independently associated with major adverse cardiovascular events (MACE), but the combined effect was far greater than any single marker alone.⁴

Biomarker Risk Strata MACE Risk Elevation (Non-users of Statins)
All Markers Low 1.00 (Reference)
High LDL-C Only +13% risk per SD
High Lp(a) Only +8% risk per SD
High hsCRP Only +6% risk per SD
Triple Elevation +77% risk (HR 1.77)

Comparison of Biomarker Risks to the Pathogenic Impact of Smoking

Smoking remains one of the most aggressive cardiovascular toxins because it generates oxidative stress, drives chronic inflammation, and directly injures the endothelium.²⁷ The question clinicians often ask is: how does smoking compare to lipid and biomarker risk?

INTERHEART provides one of the most useful comparisons because it included diverse populations across 52 countries.⁵ It showed that current smoking had one of the highest individual odds ratios for MI, but dyslipidemia (measured by ApoB/ApoA1 ratio) carried an even larger population attributable risk, because dyslipidemia is so common globally.²⁸

Risk Factor Odds Ratio (OR) for MI Population Attributable Risk (PAR)
Current Smoking 3.63 35.7% (Global)
High ApoB/ApoA1 Ratio 3.43 54.1% (Global)
Diabetes Mellitus 3.42 16.4%
Hypertension 1.89 10.7%

The Female Paradox: Sex-Specific Risk Sensitivities

Large cohorts show that women may experience a greater relative increase in MI risk from certain exposures, especially smoking and metabolic dysfunction.²⁹ In UK Biobank, current smoking was linked to a hazard ratio for MI of 3.46 in women compared with 2.23 in men, producing a ratio of hazard ratios (RHR) of 1.55.²⁹

Clinical Implications: Managing the Residual Risk Triad

Even with excellent statin therapy and strong LDL-C lowering, cardiovascular events still occur. This is often referred to as residual risk, and it commonly reflects a combination of residual particle risk (ApoB), genetic risk (Lp(a)), and residual inflammatory risk (hsCRP).³⁰

Statins lower LDL-C and reduce events, but they have little effect on Lp(a), and multiple studies suggest statins may increase Lp(a) modestly (often ~10–20%).³¹ PCSK9 inhibitors reduce LDL-C substantially and also lower Lp(a) by about ~27%.³²

The most promising future approach is direct Lp(a) lowering using antisense oligonucleotides (ASOs) or siRNA platforms, which have shown 80–90% reductions in early studies.³³ Finally, inflammation-focused trials such as CANTOS demonstrated that reducing inflammatory signaling (independent of lipids) can reduce MACE, reinforcing the clinical reality that inflammation is not just a bystander.³⁴

Conclusion: The Integrated Risk Map

Preventive cardiology is increasingly moving from a single-marker “cholesterol hypothesis” toward a more integrated approach. In practical terms, ApoB tells you particle burden, Lp(a) tells you inherited atherothrombotic risk, and hsCRP tells you about inflammatory activation. When these risks cluster, events can occur despite “good” LDL-C numbers.

Used together, these markers support more individualized decisions about therapy intensity and emerging targeted treatments—aimed at achieving the deepest possible reduction in cardiovascular risk.

References

  1. Nicholls SJ, Nelson AJ. Current perspectives on Lp(a)-lowering therapies: Who may benefit?. Kardiol Pol. 2025;83(6):688-694. doi:10.33963/v.phj.106327
  2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
  3. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813-1818. doi:10.1161/01.cir.103.13.1813
  4. Markus MRP, Ittermann T, Mariño Coronado J, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J. 2025;46(39):3863-3874. doi:10.1093/eurheartj/ehaf281
  5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9
  6. Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over. JAMA Cardiol. 2022;7(3):257-258. doi:10.1001/jamacardio.2021.5080
  7. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
  8. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016
  9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-113. doi:10.1016/j.jacl.2011.02.001
  10. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
  11. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509-515. doi:10.1161/ATVBAHA.113.300156
  12. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473-483. doi:10.1097/MOL.0000000000000330
  13. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108(2):235-248. doi:10.1161/CIRCRESAHA.110.223875
  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
  15. Albers JJ, Marcovina SM. Standardization of apolipoprotein B and A-I measurements. Clin Chem. 1989;35(7):1357-1361.
  16. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184. doi:10.1161/CIRCULATIONAHA.107.715698
  17. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52-60. doi:10.1172/JCI115855
  18. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607-614. doi:10.1007/BF00201550
  19. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167-174. doi:10.1097/00041433-200404000-00009
  20. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230-2239. doi:10.1194/jlr.M800174-JLR200
  21. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132-137. doi:10.1038/330132a0
  22. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333-343. doi:10.1016/j.clinbiochem.2003.12.007
  23. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874. doi:10.1038/nature01323
  24. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361. doi:10.1038/nature08938
  25. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
  26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
  27. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737. doi:10.1016/j.jacc.2003.12.047
  28. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224-233. doi:10.1016/S0140-6736(08)61076-4
  29. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. Published 2018 Nov 7. doi:10.1136/bmj.k4247
  30. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-1722. doi:10.1093/eurheartj/ehw024
  31. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-2284. doi:10.1093/eurheartj/ehz310
  32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
  33. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244-255. doi:10.1056/NEJMoa1905239
  34. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914

Transparency Note: This blog post was created with assistance from AI tools. The final content has been carefully reviewed and edited by the author, who is responsible for its accuracy. The information provided is for educational purposes only and does not constitute medical advice.

Editorial and AI Transparency statement

Share This Post

Related Articles

Watch on YouTube
AI App

Heart Risk Calulator

Educational family-history heart risk calculator with H-score insights, visual family tree input and shareable PDF reports.

Read why this app is so important here.